Rathbones Group PLC Abb Vie Inc. Transaction History

Rathbones Group PLC

$19 Billion
Q3 2024

A detailed history of Rathbones Group PLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Rathbones Group PLC holds 89,755 shares of ABBV stock, worth $16.2 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

89,755

Previous 94,284 4.8%

Holding current value

$16.2 Million

Previous $16.2 Million 9.6%

% of portfolio

0.09%

Previous 0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$163.84 - $199.33 $742,031 - $902,765	-4,529 Reduced 4.8%	89,755 $17.7 Million
Q2 2024 Aug 09, 2024	SELL	$154.79 - $180.76 $625,196 - $730,089	-4,039 Reduced 4.11%	94,284 $16.2 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $1.27 Million - $1.45 Million	-7,961 Reduced 7.49%	98,323 $17.9 Million
Q4 2023 Feb 13, 2024	SELL	$137.6 - $154.97 $402,067 - $452,822	-2,922 Reduced 2.68%	106,284 $16.5 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $2.17 Million - $2.52 Million	16,280 Added 17.52%	109,206 $16.3 Million
Q2 2023 Aug 04, 2023	SELL	$132.51 - $164.9 $227,917 - $283,628	-1,720 Reduced 1.82%	92,926 $12.5 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $600,709 - $691,807	-4,154 Reduced 4.2%	94,646 $15.1 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $253,660 - $304,205	-1,834 Reduced 1.82%	98,800 $16 Million
Q3 2022 Nov 03, 2022	BUY	$134.21 - $153.93 $2,281 - $2,616	17 Added 0.02%	100,634 $13.5 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $76,654 - $97,452	-557 Reduced 0.55%	100,617 $15.4 Million
Q1 2022 May 11, 2022	SELL	$131.98 - $163.75 $70,609 - $87,606	-535 Reduced 0.53%	101,174 $16.4 Million
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $63,813 - $80,742	594 Added 0.59%	101,709 $13.8 Million
Q3 2021 Nov 04, 2021	SELL	$106.4 - $120.78 $521,147 - $591,580	-4,898 Reduced 4.62%	101,115 $10.9 Million
Q2 2021 Jul 30, 2021	BUY	$105.21 - $117.21 $127,198 - $141,706	1,209 Added 1.15%	106,013 $11.9 Million
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $117,235 - $129,062	1,146 Added 1.11%	104,804 $11.3 Million
Q4 2020 Feb 11, 2021	SELL	$80.49 - $108.67 $377,015 - $509,010	-4,684 Reduced 4.32%	103,658 $11.1 Million
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $87,112 - $102,241	-1,014 Reduced 0.93%	108,342 $9.49 Million
Q2 2020 Aug 07, 2020	SELL	$73.37 - $98.18 $168,237 - $225,126	-2,293 Reduced 2.05%	109,356 $10.7 Million
Q1 2020 May 04, 2020	SELL	$64.5 - $97.79 $23,929 - $36,280	-371 Reduced 0.33%	111,649 $8.51 Million
Q4 2019 Feb 11, 2020	BUY	$72.13 - $90.25 $113,316 - $141,782	1,571 Added 1.42%	112,020 $9.92 Million
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $2.35 Million - $2.83 Million	37,314 Added 51.02%	110,449 $8.36 Million
Q2 2019 Aug 12, 2019	SELL	$65.7 - $83.98 $375,804 - $480,365	-5,720 Reduced 7.25%	73,135 $5.32 Million
Q1 2019 May 09, 2019	SELL	$77.14 - $90.79 $350,601 - $412,640	-4,545 Reduced 5.45%	78,855 $6.36 Million
Q4 2018 Feb 12, 2019	SELL	$77.85 - $96.01 $325,023 - $400,841	-4,175 Reduced 4.77%	83,400 $7.69 Million
Q3 2018 Oct 12, 2018	SELL	$88.91 - $98.84 $26,673 - $29,652	-300 Reduced 0.34%	87,575 $8.28 Million
Q2 2018 Jul 16, 2018	SELL	$89.78 - $106.23 $677,839 - $802,036	-7,550 Reduced 7.91%	87,875 $8.14 Million
Q1 2018 Apr 06, 2018	SELL	$92.01 - $123.21 $813,368 - $1.09 Million	-8,840 Reduced 8.48%	95,425 $9.03 Million
Q4 2017 Jan 24, 2018	SELL	$89.56 - $98.21 $68,961 - $75,621	-770 Reduced 0.73%	104,265 $10.1 Million
Q3 2017 Oct 24, 2017	BUY	$69.85 - $89.22 $7.34 Million - $9.37 Million	105,035	105,035 $9.33 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.

Account

Rathbones Group PLC Abb Vie Inc. Transaction History